With CURE TV®, you have access to a variety of informative and uplifting videos. You’ll find interviews with cancer experts, advocates, patients, caregivers, as well as highlights from our celebratory events showcasing interviews with award winners and celebrity speakers.
Greenberger Explains Why Immunotherapy Will Be an Important Class of Therapies for Blood Cancers
December 10th 2014Lee Greenberger, of the Leukemia & Lymphoma Society, explains how immunotherapy research has progressed in hematological cancers and the potential for these burgeoning therapies.
Read More
David Alexander on the MPN Heroes Program
December 6th 2014David Alexander was selected as an MPN Hero at this year's MPN Heroes event. The MPN Heroes event honors clinicians, caregivers, and advocates who have made significant contributions in the field of myeloproliferative neoplasms (MPNs).
Read More
Artist's Balancing Act Inspires New York's Hope Murals Project
November 13th 2014New York artist and GIST survivor, Ellen Mayer, painted "Balancing Act" to describe how she felt about her cancer experience. The artwork was later selected as one of 10 pieces to be publicly painted for The Hope Murals Project.
Read More
Oncology on Canvas and The Hope Murals Project Reaches New York City
October 31st 2014For the 10th anniversary of the Oncology on Canvas art competition, Lilly Oncology and the National Coalition for Cancer Survivorship created The Hope Murals Project, a traveling exhibit throughout the U.S.
Read More
Latest Updates in Cancer Research Announced at European Oncology Congress
October 9th 2014Several studies announcing the latest research in different cancers, including prostate, breast and lung cancers, were presented at the 2014 European Society of Medical Oncology's annual meeting in Madrid, Spain.
Read More
ASCO: Early Studies Show Promise in Treating Metastatic Breast Cancer
June 5th 2014Debu Tripathy, MD, editor-in-chief of CURE magazine, shares the latest research in metastatic breast cancer, including targeted drugs being tested in early-phase studies that appear promising, including the PARP inhibitor veliparib, the CDK4/6 inhibitor palbociclib and the anti-angiogenesis drug trametinib.
Read More